|
||
 |
The Peabody Orlando, Orlando, Florida - March 8, 2005 This online CME activity is based on presentations at the CME symposium titled "The Endocannabinoid System and Its Impact on Excess Visceral Fat: A New Paradigm in Metabolic and Cardiovascular Risk Management," which was held on March 8, 2005, at the American College of Cardiology meeting in Orlando, Florida. Persons who attended the symposium are NOT eligible for AMA PRA Category 1 Credit™ for completing this enduring material. Please note that the course is accredited only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Essential Areas and Policies regarding commercial support, participants are advised that 1 or more presentations in this continuing medical education activity may contain references to off-label or unapproved uses of drugs or devices. Participants should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Policies. © 2005-2006 Discovery Institute of Medical Education
Activity Purpose The purpose of this CME activity is to inform cardiologists and other physicians of a novel therapy to manage cardiovascular disease risk factors specifically related to excess visceral fat and smoking by modulating the endocannabinoid system via the administration of cannabinoid CB1 blockade. Statement of Need Already a major health issue in the United States, the impact of obesity has also become an issue worthy of worldwide concern. Obesity plays a central role in a constellation of morbidities, including CVD, diabetes, and related metabolic and vascular disorders (eg, dyslipidemia, hypertension). A recent study implicates the endocannabinoid (EC) system as a significant contributor to metabolic homeostasis. EC receptors have been detected centrally, peripherally, and in endocrine and related tissues. Overstimulation of the EC system can result in excess visceral fat and the ensuing morbidities of CVD, diabetes, and metabolic disorders, which are thought to be mitigated by EC blockade. EC blockade is also believed to play a significant role in smoking cessation. This course explains the EC system and discusses the potential for multirisk management through regulation of the system. Learning Objectives Upon completion of this activity, participants should be able to
Accreditation Statement The Discovery Institute of Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement The Discovery Institute of Medical Education designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All participants are required to complete an evaluation form and pass a course test (both online) before receiving their continuing education certificates (via email and/or PDF download). No fees are charged to participate in the program or to receive the certificate. Faculty Disclosures The Discovery Institute of Medical Education requires that the faculty participating in a continuing medical education activity disclose to participants any significant financial interest or other relationship (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. This CME activity may include discussions regarding the use of medications that may be outside of the approved labeling for these products. Physicians should consult the current prescribing information for these products. The Discovery Institute of Medical Education requires faculty members to disclose that a product is not labeled for the use under discussion. Compliance is documentation that demonstrates the provider has a practice in place to make this requirement known to the faculty. Robert M. Anthenelli, MD Christie M. Ballantyne, MD Christopher P. Cannon, MD Jean-Pierre Després, PhD Luc Van Gaal, MD, PhD Instructions to Participants Course participants will view audio/slide presentations and then must successfully complete a test in order to receive continuing medical education credit. Full instructions are available on the user instructions page. Disclaimer The opinions expressed herein are those of the faculty and do not necessarily represent the views of the sponsor, accrediting body, or publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects, before administering pharmacologic therapy to patients. Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the sponsor, accrediting body, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, nor are they responsible for omissions or errors, or the results of using information provided in this course. The participant should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts. Click here to view minimum system requirements.
|
|
